Janssen Scientific Affairs
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Janssen Scientific Affairs sits in the top decile of US sponsors by registered trial count (#456 of 15,742 sponsors by registered trial count).
Janssen Scientific Affairs: 37 sponsored US clinical trials, 1 recruiting.
Janssen Scientific Affairs sponsors 37 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 32 completed. 14 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Crohn Disease, with 2 trials.
Top-decile sponsor footprint
Janssen Scientific Affairs ranks in the top decile of sponsors by registered trial count (#456 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
32 of 35 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
37 total, page 1 of 1
A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis
NCT04372108
Psoriasis Longitudinal Assessment and Registry
NCT00508547
A Study to Assess the Engagement and Usefulness of Care4Today Digital Platform for Disease Management in Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD) Population
NCT06052319
A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma
NCT05347485
A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain
NCT04442737
A Study to Investigate if Early Atrial Fibrillation (AF) Diagnosis Reduces Risk of Events Like Stroke in the Real-World
NCT04276441
Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year
NCT03464136
A Study to Quantify Use of Anticoagulation to Improve Management of Atrial Fibrillation
NCT03382613
A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care
NCT03227861
Multiple Myeloma Patient Registry
NCT03180853
A Study to Assess the Validation and Mapping of the Suicide Ideation and Behavior Assessment
NCT03085108
Sustainable Early Episode Clinic Study (SEEC)
NCT03571685
Smartphones to Improve Rivaroxaban ADHEREnce in Atrial Fibrillation
NCT02996435
Study to Evaluate the Relative Bioavailability of Fixed-dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) as a Whole Tablet, as a Split Tablet, and as Crushed Tablet in Healthy Adult Participants
NCT02984852
A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma
NCT02951819
An Efficacy and Safety Study of Infliximab Dose Escalation in Pediatric Participants With Inflammatory Bowel Disease
NCT02566889
Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis
NCT02728934
Real-World Study of Enzalutamide and Abiraterone Acetate (With Prednisone) Tolerability
NCT02663193
A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department
NCT02584660
A Study to Assess the Independent Effects of 4-Factor Prothrombin Complex Concentrate and Tranexamic Acid on Bleeding/Pharmacodynamics in Healthy Participants
NCT02561923
Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)
NCT02600741
A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform
NCT02431702
Study to Evaluate the Effects of Tramadol Hydrochloride on Cardiac Repolarization in Healthy Participants
NCT02307864
An Efficacy and Safety Study of Simeprevir and Sofosbuvir With and Without Ribavirin in Participants With Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant
NCT02165189
A Study to Examine Patient Characteristics, Health Care Management and Health Outcomes of Hepatitis C Virus (HCV) Patients Treated With Simeprevir
NCT02103699
Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents
NCT01939496
A Dose Ranging Escalation Study of Tramadol Hydrochloride in Healthy Volunteers
NCT01947920
A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention
NCT01830543
A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL)
NCT01804166
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)
NCT01701817
A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy
NCT01729871
Pharmacokinetics Study of Oral Rivaroxaban in Healthy Participants
NCT01464450
A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder
NCT01193153
Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations
NCT01181960
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
NCT01165710
15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated
NCT01157351
A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women
NCT00855335
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 3 |
| Phase 3 | 7 |
| Phase 4 | 7 |
Where Janssen Scientific Affairs enrollment is open (later-stage tilt)
1 recruiting of 37 indexed (3% open); 32 completed (86%).
Phase mix: 14 late (III/IV) vs 8 early (I/II) (later-stage heavy).
Top condition: Crohn Disease (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Janssen Scientific Affairs: open-pipeline peers nationwide
Peers matched on 37 registered trials and 3% open enrollment, not the therapeutic-area sidebar.
Janssen Scientific Affairs sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 37 trials (± recruiting share)
- Appalachian State University · 37 trials · 3% recruiting
- Bracco Diagnostics · 37 trials · 3% recruiting
- Carnegie Mellon University · 37 trials · 11% recruiting
- Cutera · 37 trials · 0% recruiting
Sponsors near 3% open enrollment (± trial volume)
- Nektar Therapeutics · 3% recruiting · 37 trials
- Enanta Pharmaceuticals · 3% recruiting · 36 trials
- Eastern Cooperative Oncology Group · 3% recruiting · 141 trials
- Ethicon Endo-Surgery · 3% recruiting · 39 trials
Related
What to do with this Janssen Scientific Affairs page
37 registered trials is a research-attention snapshot, not an endorsement of Janssen Scientific Affairs or any single study.
- 1 of Janssen Scientific Affairs's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Crohn Disease is the condition Janssen Scientific Affairs studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Crohn Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Janssen Scientific Affairs pipeline card: 37 registered trials from official public datasets.Report a data error.